Effect of dose reductions on clinical outcomes, or of outcomes on dose reductions?
Breast. 2022 Jan 3:S0960-9776(21)01027-4. doi: 10.1016/j.breast.2021.12.020. Online ahead of print.NO ABSTRACTPMID:35012846 | DOI:10.1016/j.breast.2021.12.020 (Source: Breast)
Source: Breast - January 11, 2022 Category: Cancer & Oncology Authors: Meredith M Regan Source Type: research

A multidisciplinary approach to optimizing care of patients treated with alpelisib
CONCLUSION: Overall, alpelisib-associated AEs are generally manageable with prompt recognition, regular monitoring, and appropriate intervention, preferably with a multidisciplinary approach.PMID:35016012 | PMC:PMC8749445 | DOI:10.1016/j.breast.2021.12.016 (Source: Breast)
Source: Breast - January 11, 2022 Category: Cancer & Oncology Authors: Hope S Rugo Mario E Lacouture Marcus D Goncalves Umesh Masharani Matti S Aapro Joyce A O'Shaughnessy Source Type: research

Effect of dose reductions on clinical outcomes, or of outcomes on dose reductions?
Breast. 2022 Jan 3:S0960-9776(21)01027-4. doi: 10.1016/j.breast.2021.12.020. Online ahead of print.NO ABSTRACTPMID:35012846 | DOI:10.1016/j.breast.2021.12.020 (Source: Breast)
Source: Breast - January 11, 2022 Category: Cancer & Oncology Authors: Meredith M Regan Source Type: research

A multidisciplinary approach to optimizing care of patients treated with alpelisib
CONCLUSION: Overall, alpelisib-associated AEs are generally manageable with prompt recognition, regular monitoring, and appropriate intervention, preferably with a multidisciplinary approach.PMID:35016012 | PMC:PMC8749445 | DOI:10.1016/j.breast.2021.12.016 (Source: Breast)
Source: Breast - January 11, 2022 Category: Cancer & Oncology Authors: Hope S Rugo Mario E Lacouture Marcus D Goncalves Umesh Masharani Matti S Aapro Joyce A O'Shaughnessy Source Type: research

Effect of dose reductions on clinical outcomes, or of outcomes on dose reductions?
Breast. 2022 Jan 3:S0960-9776(21)01027-4. doi: 10.1016/j.breast.2021.12.020. Online ahead of print.NO ABSTRACTPMID:35012846 | DOI:10.1016/j.breast.2021.12.020 (Source: Breast)
Source: Breast - January 11, 2022 Category: Cancer & Oncology Authors: Meredith M Regan Source Type: research

A multidisciplinary approach to optimizing care of patients treated with alpelisib
CONCLUSION: Overall, alpelisib-associated AEs are generally manageable with prompt recognition, regular monitoring, and appropriate intervention, preferably with a multidisciplinary approach.PMID:35016012 | PMC:PMC8749445 | DOI:10.1016/j.breast.2021.12.016 (Source: Breast)
Source: Breast - January 11, 2022 Category: Cancer & Oncology Authors: Hope S Rugo Mario E Lacouture Marcus D Goncalves Umesh Masharani Matti S Aapro Joyce A O'Shaughnessy Source Type: research

Effect of dose reductions on clinical outcomes, or of outcomes on dose reductions?
Breast. 2022 Jan 3:S0960-9776(21)01027-4. doi: 10.1016/j.breast.2021.12.020. Online ahead of print.NO ABSTRACTPMID:35012846 | DOI:10.1016/j.breast.2021.12.020 (Source: Breast)
Source: Breast - January 11, 2022 Category: Cancer & Oncology Authors: Meredith M Regan Source Type: research

A multidisciplinary approach to optimizing care of patients treated with alpelisib
CONCLUSION: Overall, alpelisib-associated AEs are generally manageable with prompt recognition, regular monitoring, and appropriate intervention, preferably with a multidisciplinary approach.PMID:35016012 | DOI:10.1016/j.breast.2021.12.016 (Source: Breast)
Source: Breast - January 11, 2022 Category: Cancer & Oncology Authors: Hope S Rugo Mario E Lacouture Marcus D Goncalves Umesh Masharani Matti S Aapro Joyce A O'Shaughnessy Source Type: research

Effect of dose reductions on clinical outcomes, or of outcomes on dose reductions?
Breast. 2022 Jan 3:S0960-9776(21)01027-4. doi: 10.1016/j.breast.2021.12.020. Online ahead of print.NO ABSTRACTPMID:35012846 | DOI:10.1016/j.breast.2021.12.020 (Source: Breast)
Source: Breast - January 11, 2022 Category: Cancer & Oncology Authors: Meredith M Regan Source Type: research

A multidisciplinary approach to optimizing care of patients treated with alpelisib
CONCLUSION: Overall, alpelisib-associated AEs are generally manageable with prompt recognition, regular monitoring, and appropriate intervention, preferably with a multidisciplinary approach.PMID:35016012 | DOI:10.1016/j.breast.2021.12.016 (Source: Breast)
Source: Breast - January 11, 2022 Category: Cancer & Oncology Authors: Hope S Rugo Mario E Lacouture Marcus D Goncalves Umesh Masharani Matti S Aapro Joyce A O'Shaughnessy Source Type: research

Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer
CONCLUSIONS: T-DXd demonstrated favorable activity in clinical practice. Moreover, T-DXd showed meaningful benefit in patients with heterogeneity, reduction, or loss of HER2 expression.PMID:34999427 | DOI:10.1016/j.breast.2022.01.002 (Source: Breast)
Source: Breast - January 9, 2022 Category: Cancer & Oncology Authors: Hiromichi Nakajima Kenichi Harano Tokiko Nakai Shota Kusuhara Takehiro Nakao Chikako Funasaka Chihiro Kondoh Nobuaki Matsubara Yoichi Naito Ako Hosono Shuichi Mitsunaga Genichiro Ishii Toru Mukohara Source Type: research

Unresected screen-detected ductal carcinoma in situ: Outcomes of 311 women in the Forget-Me-Not 2 study
CONCLUSION: The findings suggest that active surveillance may be a reasonable alternative to surgery in patients with low grade DCIS but that women with intermediate or high grade disease should continue to be offered surgery. This highlights the importance of reproducible grading of DCIS to ensure patients receive appropriate treatment.PMID:34999428 | DOI:10.1016/j.breast.2022.01.001 (Source: Breast)
Source: Breast - January 9, 2022 Category: Cancer & Oncology Authors: Anthony J Maxwell Bridget Hilton Karen Clements David Dodwell Joanne Dulson-Cox Olive Kearins Cliona Kirwan Janet Litherland Senthurun Mylvaganam Elena Provenzano Sarah E Pinder Elinor Sawyer Abeer M Shaaban Nisha Sharma Hilary Stobart Matthew G Wallis Al Source Type: research

Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer
CONCLUSIONS: T-DXd demonstrated favorable activity in clinical practice. Moreover, T-DXd showed meaningful benefit in patients with heterogeneity, reduction, or loss of HER2 expression.PMID:34999427 | DOI:10.1016/j.breast.2022.01.002 (Source: Breast)
Source: Breast - January 9, 2022 Category: Cancer & Oncology Authors: Hiromichi Nakajima Kenichi Harano Tokiko Nakai Shota Kusuhara Takehiro Nakao Chikako Funasaka Chihiro Kondoh Nobuaki Matsubara Yoichi Naito Ako Hosono Shuichi Mitsunaga Genichiro Ishii Toru Mukohara Source Type: research

Unresected screen-detected ductal carcinoma in situ: Outcomes of 311 women in the Forget-Me-Not 2 study
CONCLUSION: The findings suggest that active surveillance may be a reasonable alternative to surgery in patients with low grade DCIS but that women with intermediate or high grade disease should continue to be offered surgery. This highlights the importance of reproducible grading of DCIS to ensure patients receive appropriate treatment.PMID:34999428 | DOI:10.1016/j.breast.2022.01.001 (Source: Breast)
Source: Breast - January 9, 2022 Category: Cancer & Oncology Authors: Anthony J Maxwell Bridget Hilton Karen Clements David Dodwell Joanne Dulson-Cox Olive Kearins Cliona Kirwan Janet Litherland Senthurun Mylvaganam Elena Provenzano Sarah E Pinder Elinor Sawyer Abeer M Shaaban Nisha Sharma Hilary Stobart Matthew G Wallis Al Source Type: research

Immune checkpoint inhibition in the treatment of early stage triple negative breast cancer: 2021 update
Breast. 2021 Dec 31:S0960-9776(21)01025-0. doi: 10.1016/j.breast.2021.12.018. Online ahead of print.ABSTRACTThere is an emerging body of evidence regarding the use of immunotherapy in early-stage triple negative breast cancer (TNBC), with the recent publication of several phase III and randomised phase II studies examining the role of immune checkpoint inhibitors (ICI) in the neoadjuvant setting in combination with chemotherapy. Evidence to date suggests that the addition of PD-1/PD-L1 inhibitors results in slight increases in the rate of pathologic complete response (pCR) seen at the time of surgery, and improved event fr...
Source: Breast - January 8, 2022 Category: Cancer & Oncology Authors: Lauren C Brown Sherene Loi Source Type: research

Neoadjuvant approach in patients with early breast cancer: patient assessment, staging, and planning
Breast. 2021 Dec 31:S0960-9776(21)01026-2. doi: 10.1016/j.breast.2021.12.019. Online ahead of print.ABSTRACTNeoadjuvant treatment (NAT) has become an option in early stage (stage I-II) breast cancer (EBC). New advances in systemic and targeted therapies have increased rates of pathologic complete response increasing the number of patients undergoing NAT. Clear benefits of NAT are downstaging the tumor and the axillary nodes to de-escalate surgery and to evaluate response to treatment. Selection of patients for NAT in EBC rely in several factors that are related to patient characteristics (i.e, age and comorbidities), to tu...
Source: Breast - January 8, 2022 Category: Cancer & Oncology Authors: Isabel T Rubio Carolina Sobrido Source Type: research

Statin use and patterns of breast cancer recurrence in the Malm ö Diet and Cancer Study
CONCLUSION: In the MDCS, statin use was associated with a reduced risk of distant breast cancer recurrence, whereas no association between statin use and loco-regional breast cancer recurrence was found. This site-based difference in disease recurrence may be explained by statin's inhibition of epithelial-mesenchymal transition.PMID:34995921 | DOI:10.1016/j.breast.2022.01.003 (Source: Breast)
Source: Breast - January 7, 2022 Category: Cancer & Oncology Authors: Maria Inasu Maria Feldt Helena Jernstr öm Signe Borgquist Sixten Harborg Source Type: research

Real world initial palliative treatment patterns and clinical outcomes in premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A study of the National Cancer Center, China
CONCLUSION: In real world, a high percentage of premenopausal patients with HR + HER2- disease received chemotherapy as initial palliative treatment in China, which was not associated with worsened survival. Further studies with larger sample size across China are needed to explore the relationship between this guideline non-adherence and clinical outcomes.PMID:34995922 | DOI:10.1016/j.breast.2021.12.017 (Source: Breast)
Source: Breast - January 7, 2022 Category: Cancer & Oncology Authors: Yiqun Li Hongnan Mo Xiuwen Guan Shaoyan Lin Zijing Wang Yimeng Chen Shanshan Chen Qiao Li Ruigang Cai Jiayu Wang Yang Luo Ying Fan Peng Yuan Pin Zhang Qing Li Fei Ma Binghe Xu Source Type: research

The emerging role of real-world data in advanced breast cancer therapy: Recommendations for collaborative decision-making
Breast. 2021 Dec 22;61:118-122. doi: 10.1016/j.breast.2021.12.015. Online ahead of print.ABSTRACTAmong stakeholders and decision-makers in advanced breast cancer, the demand for insights from real-world data (RWD) is increasing. Although RWD can be used to support decisions throughout different stages of a breast cancer drug's life cycle, barriers exist to its use and acceptance. We propose a collaborative approach to generating and using RWD that is meaningful to multiple stakeholders, and encourage frameworks toward international guidelines to help standardize RWD methodologies to achieve more efficient use of RWD insigh...
Source: Breast - December 27, 2021 Category: Cancer & Oncology Authors: Paul Cottu Scott David Ramsey Oriol Sol à-Morales Patricia A Spears Lockwood Taylor Source Type: research

The emerging role of real-world data in advanced breast cancer therapy: Recommendations for collaborative decision-making
Breast. 2021 Dec 22;61:118-122. doi: 10.1016/j.breast.2021.12.015. Online ahead of print.ABSTRACTAmong stakeholders and decision-makers in advanced breast cancer, the demand for insights from real-world data (RWD) is increasing. Although RWD can be used to support decisions throughout different stages of a breast cancer drug's life cycle, barriers exist to its use and acceptance. We propose a collaborative approach to generating and using RWD that is meaningful to multiple stakeholders, and encourage frameworks toward international guidelines to help standardize RWD methodologies to achieve more efficient use of RWD insigh...
Source: Breast - December 27, 2021 Category: Cancer & Oncology Authors: Paul Cottu Scott David Ramsey Oriol Sol à-Morales Patricia A Spears Lockwood Taylor Source Type: research

The emerging role of real-world data in advanced breast cancer therapy: Recommendations for collaborative decision-making
Breast. 2021 Dec 22;61:118-122. doi: 10.1016/j.breast.2021.12.015. Online ahead of print.ABSTRACTAmong stakeholders and decision-makers in advanced breast cancer, the demand for insights from real-world data (RWD) is increasing. Although RWD can be used to support decisions throughout different stages of a breast cancer drug's life cycle, barriers exist to its use and acceptance. We propose a collaborative approach to generating and using RWD that is meaningful to multiple stakeholders, and encourage frameworks toward international guidelines to help standardize RWD methodologies to achieve more efficient use of RWD insigh...
Source: Breast - December 27, 2021 Category: Cancer & Oncology Authors: Paul Cottu Scott David Ramsey Oriol Sol à-Morales Patricia A Spears Lockwood Taylor Source Type: research

The emerging role of real-world data in advanced breast cancer therapy: Recommendations for collaborative decision-making
Breast. 2021 Dec 22;61:118-122. doi: 10.1016/j.breast.2021.12.015. Online ahead of print.ABSTRACTAmong stakeholders and decision-makers in advanced breast cancer, the demand for insights from real-world data (RWD) is increasing. Although RWD can be used to support decisions throughout different stages of a breast cancer drug's life cycle, barriers exist to its use and acceptance. We propose a collaborative approach to generating and using RWD that is meaningful to multiple stakeholders, and encourage frameworks toward international guidelines to help standardize RWD methodologies to achieve more efficient use of RWD insigh...
Source: Breast - December 27, 2021 Category: Cancer & Oncology Authors: Paul Cottu Scott David Ramsey Oriol Sol à-Morales Patricia A Spears Lockwood Taylor Source Type: research

The emerging role of real-world data in advanced breast cancer therapy: Recommendations for collaborative decision-making
Breast. 2021 Dec 22;61:118-122. doi: 10.1016/j.breast.2021.12.015. Online ahead of print.ABSTRACTAmong stakeholders and decision-makers in advanced breast cancer, the demand for insights from real-world data (RWD) is increasing. Although RWD can be used to support decisions throughout different stages of a breast cancer drug's life cycle, barriers exist to its use and acceptance. We propose a collaborative approach to generating and using RWD that is meaningful to multiple stakeholders, and encourage frameworks toward international guidelines to help standardize RWD methodologies to achieve more efficient use of RWD insigh...
Source: Breast - December 27, 2021 Category: Cancer & Oncology Authors: Paul Cottu Scott David Ramsey Oriol Sol à-Morales Patricia A Spears Lockwood Taylor Source Type: research

The emerging role of real-world data in advanced breast cancer therapy: Recommendations for collaborative decision-making
Breast. 2021 Dec 22;61:118-122. doi: 10.1016/j.breast.2021.12.015. Online ahead of print.ABSTRACTAmong stakeholders and decision-makers in advanced breast cancer, the demand for insights from real-world data (RWD) is increasing. Although RWD can be used to support decisions throughout different stages of a breast cancer drug's life cycle, barriers exist to its use and acceptance. We propose a collaborative approach to generating and using RWD that is meaningful to multiple stakeholders, and encourage frameworks toward international guidelines to help standardize RWD methodologies to achieve more efficient use of RWD insigh...
Source: Breast - December 27, 2021 Category: Cancer & Oncology Authors: Paul Cottu Scott David Ramsey Oriol Sol à-Morales Patricia A Spears Lockwood Taylor Source Type: research

De-escalating axillary surgery in early-stage breast cancer
Breast. 2021 Dec 15:S0960-9776(21)01020-1. doi: 10.1016/j.breast.2021.11.018. Online ahead of print.ABSTRACTThe role of axillary surgery has evolved over the last three decades from routine axillary lymph node dissection (ALND) to sentinel lymph node biopsy to omission of axillary surgery altogether in select patients. This evolution has been achieved through the design and conduct of multiple clinical trials demonstrating that ALND does not impact survival and is not necessary for local control in patients with early-stage breast cancer and limited nodal involvement. Importantly, this practice-changing shift mirrored the ...
Source: Breast - December 24, 2021 Category: Cancer & Oncology Authors: Eliza H Hersh Tari A King Source Type: research

De-escalating axillary surgery in early-stage breast cancer
Breast. 2021 Dec 15:S0960-9776(21)01020-1. doi: 10.1016/j.breast.2021.11.018. Online ahead of print.ABSTRACTThe role of axillary surgery has evolved over the last three decades from routine axillary lymph node dissection (ALND) to sentinel lymph node biopsy to omission of axillary surgery altogether in select patients. This evolution has been achieved through the design and conduct of multiple clinical trials demonstrating that ALND does not impact survival and is not necessary for local control in patients with early-stage breast cancer and limited nodal involvement. Importantly, this practice-changing shift mirrored the ...
Source: Breast - December 24, 2021 Category: Cancer & Oncology Authors: Eliza H Hersh Tari A King Source Type: research

De-escalating axillary surgery in early-stage breast cancer
Breast. 2021 Dec 15:S0960-9776(21)01020-1. doi: 10.1016/j.breast.2021.11.018. Online ahead of print.ABSTRACTThe role of axillary surgery has evolved over the last three decades from routine axillary lymph node dissection (ALND) to sentinel lymph node biopsy to omission of axillary surgery altogether in select patients. This evolution has been achieved through the design and conduct of multiple clinical trials demonstrating that ALND does not impact survival and is not necessary for local control in patients with early-stage breast cancer and limited nodal involvement. Importantly, this practice-changing shift mirrored the ...
Source: Breast - December 24, 2021 Category: Cancer & Oncology Authors: Eliza H Hersh Tari A King Source Type: research

De-escalating axillary surgery in early-stage breast cancer
Breast. 2021 Dec 15:S0960-9776(21)01020-1. doi: 10.1016/j.breast.2021.11.018. Online ahead of print.ABSTRACTThe role of axillary surgery has evolved over the last three decades from routine axillary lymph node dissection (ALND) to sentinel lymph node biopsy to omission of axillary surgery altogether in select patients. This evolution has been achieved through the design and conduct of multiple clinical trials demonstrating that ALND does not impact survival and is not necessary for local control in patients with early-stage breast cancer and limited nodal involvement. Importantly, this practice-changing shift mirrored the ...
Source: Breast - December 24, 2021 Category: Cancer & Oncology Authors: Eliza H Hersh Tari A King Source Type: research

Effect of postmastectomy radiotherapy on pT < sub > 1-2 < /sub > N < sub > 1 < /sub > breast cancer patients with different molecular subtypes
Breast. 2021 Dec 17;61:108-117. doi: 10.1016/j.breast.2021.12.013. Online ahead of print.ABSTRACTOBJECTIVE: To clarify the effect of postmastectomy radiotherapy (PMRT) on pT1-2N1 breast cancer patients with different molecular subtypes.METHODS: We retrospectively analyzed the data of 5442 patients with pT1-2N1 breast cancer treated using modified radical mastectomy in 11 hospitals in China. Univariate, multivariate, and propensity score matching (PSM) analyses were used to evaluate the effect of PMRT on locoregional recurrence (LRR).RESULTS: With a median follow-up duration of 63.8 months, the 5-year LRR rates were 4.0% an...
Source: Breast - December 23, 2021 Category: Cancer & Oncology Authors: Xin-Yuan Guo Guang-Yi Sun Hong-Mei Wang Min Liu Yu-Jing Zhang Na Zhang Yu Tang Xu-Ran Zhao Hao Jing Hui Fang Ge Wen Qi-Shuai Guo Hong-Fen Wu Xiao-Hu Wang Chang-Ying Ma Ye-Xiong Li Jing Cheng Mei Shi Shu-Lian Wang Source Type: research

Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer
Breast. 2021 Dec 13:S0960-9776(21)01014-6. doi: 10.1016/j.breast.2021.12.008. Online ahead of print.ABSTRACTCDK4/6 inhibitors have an established role in the treatment of hormone receptor positive HER2-negative advanced breast cancer. All studies conducted in metastatic breast cancer showed a benefit in delaying progression when added to standard endocrine therapy, regardless of therapy line, pretreatment, menopausal status, site of metastasis, CDK4/6 inhibitor used and associated endocrine therapy. A benefit in overall survival has also been demonstrated. In early breast cancer, only the MonarchE study has shown an improv...
Source: Breast - December 21, 2021 Category: Cancer & Oncology Authors: Sibylle Loibl Jenny Furlanetto Source Type: research

Locally advanced breast cancer
Breast. 2021 Dec 15:S0960-9776(21)01017-1. doi: 10.1016/j.breast.2021.12.011. Online ahead of print.ABSTRACTLocally advanced breast cancer (LABC) is defined here as inoperable breast adenocarcinoma without distant metastases. Patients with LABC require a multidisciplinary approach. Given the risk of distant metastasis, staging exams are necessary. The incidence of LABC (stages IIIB and IIIC) has decreased in recent years. LABC has rarely been investigated separately: patients with LABC have participated both in clinical trials of palliative and of neoadjuvant therapy. Most trials did not analyze responses and long-term out...
Source: Breast - December 21, 2021 Category: Cancer & Oncology Authors: Stefan Aebi Per Karlsson Irene L Wapnir Source Type: research

Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer
Breast. 2021 Dec 13:S0960-9776(21)01014-6. doi: 10.1016/j.breast.2021.12.008. Online ahead of print.ABSTRACTCDK4/6 inhibitors have an established role in the treatment of hormone receptor positive HER2-negative advanced breast cancer. All studies conducted in metastatic breast cancer showed a benefit in delaying progression when added to standard endocrine therapy, regardless of therapy line, pretreatment, menopausal status, site of metastasis, CDK4/6 inhibitor used and associated endocrine therapy. A benefit in overall survival has also been demonstrated. In early breast cancer, only the MonarchE study has shown an improv...
Source: Breast - December 21, 2021 Category: Cancer & Oncology Authors: Sibylle Loibl Jenny Furlanetto Source Type: research

Locally advanced breast cancer
Breast. 2021 Dec 15:S0960-9776(21)01017-1. doi: 10.1016/j.breast.2021.12.011. Online ahead of print.ABSTRACTLocally advanced breast cancer (LABC) is defined here as inoperable breast adenocarcinoma without distant metastases. Patients with LABC require a multidisciplinary approach. Given the risk of distant metastasis, staging exams are necessary. The incidence of LABC (stages IIIB and IIIC) has decreased in recent years. LABC has rarely been investigated separately: patients with LABC have participated both in clinical trials of palliative and of neoadjuvant therapy. Most trials did not analyze responses and long-term out...
Source: Breast - December 21, 2021 Category: Cancer & Oncology Authors: Stefan Aebi Per Karlsson Irene L Wapnir Source Type: research

Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer
Breast. 2021 Dec 13:S0960-9776(21)01014-6. doi: 10.1016/j.breast.2021.12.008. Online ahead of print.ABSTRACTCDK4/6 inhibitors have an established role in the treatment of hormone receptor positive HER2-negative advanced breast cancer. All studies conducted in metastatic breast cancer showed a benefit in delaying progression when added to standard endocrine therapy, regardless of therapy line, pretreatment, menopausal status, site of metastasis, CDK4/6 inhibitor used and associated endocrine therapy. A benefit in overall survival has also been demonstrated. In early breast cancer, only the MonarchE study has shown an improv...
Source: Breast - December 21, 2021 Category: Cancer & Oncology Authors: Sibylle Loibl Jenny Furlanetto Source Type: research

Locally advanced breast cancer
Breast. 2021 Dec 15:S0960-9776(21)01017-1. doi: 10.1016/j.breast.2021.12.011. Online ahead of print.ABSTRACTLocally advanced breast cancer (LABC) is defined here as inoperable breast adenocarcinoma without distant metastases. Patients with LABC require a multidisciplinary approach. Given the risk of distant metastasis, staging exams are necessary. The incidence of LABC (stages IIIB and IIIC) has decreased in recent years. LABC has rarely been investigated separately: patients with LABC have participated both in clinical trials of palliative and of neoadjuvant therapy. Most trials did not analyze responses and long-term out...
Source: Breast - December 21, 2021 Category: Cancer & Oncology Authors: Stefan Aebi Per Karlsson Irene L Wapnir Source Type: research

Unmet challenges in systemic therapy for early stage breast cancer
Breast. 2021 Dec 13:S0960-9776(21)01015-8. doi: 10.1016/j.breast.2021.12.009. Online ahead of print.ABSTRACTDespite marked progress in outcomes for women with early stage breast cancer, unmet challenges persist. These include accounting for the cohort of tumors that do not have favorable clinical outcomes related to tumor heterogeneity, particularly the variation within the subset of ER positive breast cancer; better treatments for subsets where existing therapies are not fully effective; and the development of biomarkers to predict response or need for ongoing treatment. Beyond these tumor-related factors, there is persis...
Source: Breast - December 20, 2021 Category: Cancer & Oncology Authors: Harold J Burstein Source Type: research

Surgery and prophylactic surgery in hereditary breast cancer
Breast. 2021 Dec 13:S0960-9776(21)01016-X. doi: 10.1016/j.breast.2021.12.010. Online ahead of print.ABSTRACTWomen with hereditary breast cancer are at increased risk of second primary cancers in the ipsilateral and contralateral breast. The level of risk varies with mutation and age at first breast cancer diagnosis. These factors as well as life expectancy should be considered when selecting the surgical approach.PMID:34924253 | DOI:10.1016/j.breast.2021.12.010 (Source: Breast)
Source: Breast - December 20, 2021 Category: Cancer & Oncology Authors: Monica Morrow Source Type: research

Giving meaning to patient reported outcomes in breast reconstruction after mastectomy - A systematic review of available scores and suggestions for further research
CONCLUSIONS: The overall certainty of evidence for scores giving meaning to PROMs for breast reconstruction is low (GRADE ƟƟОО). More studies are needed to establish relevant healthy control scores and what constitutes a relevant clinical difference for patient-reported outcome measures for breast reconstruction after mastectomy. Clinical implications of the findings and suggestions for further research are suggested in the article.PMID:34929423 | DOI:10.1016/j.breast.2021.11.008 (Source: Breast)
Source: Breast - December 20, 2021 Category: Cancer & Oncology Authors: Linn Weick Fredrik Brorson Christian Jepsen Mattias Lid én Emmelie Widmark Jensen Emma Hansson Source Type: research

Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study
CONCLUSION: Risk-reducing effects of chemotherapy are substantial for at least 5 years and may be used in personalised CBC risk prediction in any case for BRCA1 mutation carriers.PMID:34929424 | DOI:10.1016/j.breast.2021.12.007 (Source: Breast)
Source: Breast - December 20, 2021 Category: Cancer & Oncology Authors: Delal Akdeniz Mark van Barele Bernadette A M Heemskerk-Gerritsen Ewout W Steyerberg Michael Hauptmann HEBON Investigators Irma van de Beek Klaartje van Engelen Marijke R Wevers Encarnacion B G ómez García Margreet G E M Ausems Lieke P V Berger Christi J Source Type: research

Unmet challenges in systemic therapy for early stage breast cancer
Breast. 2021 Dec 13:S0960-9776(21)01015-8. doi: 10.1016/j.breast.2021.12.009. Online ahead of print.ABSTRACTDespite marked progress in outcomes for women with early stage breast cancer, unmet challenges persist. These include accounting for the cohort of tumors that do not have favorable clinical outcomes related to tumor heterogeneity, particularly the variation within the subset of ER positive breast cancer; better treatments for subsets where existing therapies are not fully effective; and the development of biomarkers to predict response or need for ongoing treatment. Beyond these tumor-related factors, there is persis...
Source: Breast - December 20, 2021 Category: Cancer & Oncology Authors: Harold J Burstein Source Type: research

Surgery and prophylactic surgery in hereditary breast cancer
Breast. 2021 Dec 13:S0960-9776(21)01016-X. doi: 10.1016/j.breast.2021.12.010. Online ahead of print.ABSTRACTWomen with hereditary breast cancer are at increased risk of second primary cancers in the ipsilateral and contralateral breast. The level of risk varies with mutation and age at first breast cancer diagnosis. These factors as well as life expectancy should be considered when selecting the surgical approach.PMID:34924253 | DOI:10.1016/j.breast.2021.12.010 (Source: Breast)
Source: Breast - December 20, 2021 Category: Cancer & Oncology Authors: Monica Morrow Source Type: research

The impact of young age at diagnosis (age & lt;40 years) on prognosis varies by breast cancer subtype: A U.S. SEER database analysis
Breast. 2021 Dec 13;61:77-83. doi: 10.1016/j.breast.2021.12.006. Online ahead of print.ABSTRACTPURPOSE: Women under 40 years old are at increased risk for developing human epidermal growth factor receptor 2 (HER2) positive or triple negative subtype and more advanced breast cancer, yet young age itself has also historically been an independent prognostic factor.METHODS: Using the Surveillance, Epidemiology, and End Results (SEER) Program, we examined data for 271,173 women with stage I-III breast cancer between 2010 and 2015. Using Fine and Gray regression models to account for competing risks, we examined the risk of brea...
Source: Breast - December 19, 2021 Category: Cancer & Oncology Authors: Hee Jeong Kim Seonok Kim Rachel A Freedman Ann H Partridge Source Type: research

Is sarcopenia a missed factor in the management of patients with metastatic breast cancer?
Breast. 2021 Dec 15;61:84-90. doi: 10.1016/j.breast.2021.12.014. Online ahead of print.ABSTRACTBACKGROUND: Sarcopenia has emerged as an important parameter to predict outcomes and treatment toxicity. However, limited data are available to assess sarcopenia prevalence in metastatic breast cancer and to evaluate its management.METHODS: The SCAN study was a cross-sectional multicenter French study that aimed to estimate sarcopenia prevalence in a real-life sample of metastatic cancer patients. Sarcopenia was identified by low muscle mass (estimated from the skeletal muscle index at the third lumbar, via computed tomography) a...
Source: Breast - December 19, 2021 Category: Cancer & Oncology Authors: Elise Deluche Denis Lachatre Mario Di Palma H élène Simon Valentin Tissot Damien Vansteene Philippe Meingan Alexis Mohebi Gr égory Lenczner Francois Pigneur Francois Goldwasser Bruno Raynard SCAN Study Group Source Type: research

Accelerating progress in early triple-negative breast cancer: A viewpoint on antibody-drug conjugates, back from St Gallen breast cancer conference 2021
Breast. 2021 Dec 13:S0960-9776(21)01018-3. doi: 10.1016/j.breast.2021.12.012. Online ahead of print.NO ABSTRACTPMID:34920925 | DOI:10.1016/j.breast.2021.12.012 (Source: Breast)
Source: Breast - December 18, 2021 Category: Cancer & Oncology Authors: Dario Trapani Giuseppe Curigliano Source Type: research

Accelerating progress in early triple-negative breast cancer: A viewpoint on antibody-drug conjugates, back from St Gallen breast cancer conference 2021
Breast. 2021 Dec 13:S0960-9776(21)01018-3. doi: 10.1016/j.breast.2021.12.012. Online ahead of print.NO ABSTRACTPMID:34920925 | DOI:10.1016/j.breast.2021.12.012 (Source: Breast)
Source: Breast - December 18, 2021 Category: Cancer & Oncology Authors: Dario Trapani Giuseppe Curigliano Source Type: research

BRCA1/2 testing for genetic susceptibility to cancer after 25 years: A scoping review and a primer on ethical implications
CONCLUSIONS: Multidisciplinary ethical discussion is necessary to guide not only individual decision making but also societal practices and medical guidelines in light of the new technologies available and the latest results regarding psychological, social, and health outcomes in cancer previvors and survivors affected by BRCA mutations.PMID:34920368 | DOI:10.1016/j.breast.2021.12.005 (Source: Breast)
Source: Breast - December 17, 2021 Category: Cancer & Oncology Authors: Dafina Petrova Maite Cruz Mar ía-José Sánchez Source Type: research

Cost-effectiveness of abbreviated-protocol MRI screening for women with mammographically dense breasts in a national breast cancer screening program
CONCLUSION: Population-based biennial breast cancer screening with AP-MRI from age 50-65 for women with extremely dense breasts might be a cost-effective alternative to mammography, but is not an option for women with heterogeneously dense breasts.PMID:34915447 | DOI:10.1016/j.breast.2021.12.004 (Source: Breast)
Source: Breast - December 16, 2021 Category: Cancer & Oncology Authors: Jing Wang Marcel J W Greuter Karin M Vermeulen Frank B Brokken Monique D Dorrius Wenli Lu Geertruida H de Bock Source Type: research

Cost-effectiveness of abbreviated-protocol MRI screening for women with mammographically dense breasts in a national breast cancer screening program
CONCLUSION: Population-based biennial breast cancer screening with AP-MRI from age 50-65 for women with extremely dense breasts might be a cost-effective alternative to mammography, but is not an option for women with heterogeneously dense breasts.PMID:34915447 | DOI:10.1016/j.breast.2021.12.004 (Source: Breast)
Source: Breast - December 16, 2021 Category: Cancer & Oncology Authors: Jing Wang Marcel J W Greuter Karin M Vermeulen Frank B Brokken Monique D Dorrius Wenli Lu Geertruida H de Bock Source Type: research

Development of novel agents for the treatment of early estrogen receptor positive breast cancer
Breast. 2021 Nov 16:S0960-9776(21)00989-9. doi: 10.1016/j.breast.2021.11.007. Online ahead of print.ABSTRACTEstrogen receptor (ER+) breast cancer is the most frequently diagnosed breast cancer subtype. Currently, adjuvant treatment for early stage disease consists of endocrine therapy, with or without chemotherapy and bone-targeted therapy, delivered in a risk-adapted manner. Despite this multimodal approach, a significant proportion of high risk patients will develop incurable distant recurrences. There is an ongoing need to develop new treatment strategies that address the biologic causes of treatment failure and to iden...
Source: Breast - December 14, 2021 Category: Cancer & Oncology Authors: Mitchell J Elliott David W Cescon Source Type: research

Development of novel agents for the treatment of early estrogen receptor positive breast cancer
Breast. 2021 Nov 16:S0960-9776(21)00989-9. doi: 10.1016/j.breast.2021.11.007. Online ahead of print.ABSTRACTEstrogen receptor (ER+) breast cancer is the most frequently diagnosed breast cancer subtype. Currently, adjuvant treatment for early stage disease consists of endocrine therapy, with or without chemotherapy and bone-targeted therapy, delivered in a risk-adapted manner. Despite this multimodal approach, a significant proportion of high risk patients will develop incurable distant recurrences. There is an ongoing need to develop new treatment strategies that address the biologic causes of treatment failure and to iden...
Source: Breast - December 14, 2021 Category: Cancer & Oncology Authors: Mitchell J Elliott David W Cescon Source Type: research